Navigation Links
Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
Date:1/13/2014

SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., an industry leader in RNA technologies, today announced its flagship program – an RNAi therapeutic targeting transthyretin (TTR)-mediated amyloidosis.  Preclinical non-human primate data will be presented at the Biotech Showcase being held January 13, 2014 in San Francisco, California.

(Logo: http://photos.prnewswire.com/prnh/20130531/MM24393LOGO)

Preclinical results from a non-human primate (NHP) study demonstrated > 75% knockdown of serum TTR protein levels after 10 days, with the effect sustained over 3 weeks (0.3 mg/kg, i.v. dosing).

In addition to NHP knockdown data, no adverse events were observed using Arcturus LUNARTM delivery technology, in particular, no injection site reactions occurred. Furthermore, a substantial safety window was demonstrated in a multiple dose rat toxicology study – no adverse events observed at the highest doses (30 mg/kg total; administered three times at 10 mg/kg over 15 days). Serum levels of the alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were determined after intravenous administration and no changes in these liver enzymes were observed.

"We are pleased to announce our flagship program targeting TTR including our successful achievement of non-human primate data with durable biological effect and having an impressive safety profile," said Pad Chivukula, Ph.D., Arcturus' CSO and COO. "With this data in hand, we are laser-focused on selecting a wholly-owned clinical drug candidate in 2014 and entering the clinic soon after."

About Transthyretin (TTR)-Mediated Amyloidosis

Transthyretin (TTR)-mediated amyloidosis is a genetically mediated fatal disease caused by mutations in the TTR gene. Mutated TTR, wh
'/>"/>

SOURCE Arcturus Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
6. Cell Therapeutics, Inc. (CTI) Reduces Net Loss for Third Quarter and Nine Months Ended September 30, 2012 Compared to Same Periods in 2011
7. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
8. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
9. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
10. Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)
11. Arno Therapeutics, Inc. Appoints Randy Thurman to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015 VWR (NASDAQ: VWR ), ... announces the redesign of its global website, www.vwr.com , ... visiting the new site, guests will enjoy enhanced content on ... images.  Each country site now includes: , ... menu; and , the ability to search by discipline/industry. ...
(Date:8/3/2015)... 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) ... Quarter 2015 Investor Conference Call and webcast at 4:30 p.m., ... call will cover an update on Merrimack,s progress as ... A press release detailing the information to be discussed ... Monday, August 10. Investors and the general public are ...
(Date:8/3/2015)... and FLORHAM PARK, N.J. ... that once-daily naldemedine met its primary and secondary endpoints ... treatment of opioid-induced constipation (OIC) in adult patients with ... acting mu-opioid receptor antagonist (PAMORA). This is the third ... and key secondary endpoints. Study results showed ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... Orbitz Worldwide, Inc. (NYSE: OWW ) will host a conference call to ... on Wednesday, May 5, 2010 at 10:00 a.m. EDT ( 9:00 ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20070813/AQM125LOGO ) , ... A live webcast of the call can be accessed through the Orbitz Worldwide ...
... April 26 Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced ... will present at Deutsche Bank,s 35th Annual Health Care Conference on Monday, ... InterContinental Boston Hotel in Boston, MA. , ... A live webcast of the presentation may be accessed from the ...
Cached Medicine Technology:Orbitz Worldwide, Inc. to Host First Quarter 2010 Earnings Call on May 5 2Orbitz Worldwide, Inc. to Host First Quarter 2010 Earnings Call on May 5 3
(Date:8/4/2015)... ... August 04, 2015 , ... More than 700 years of marital bliss ... on Friday, July 24th. Chaplains Shawn Kafader and Richard Oas lead the non-denominational ... the ceremony was a reception, with music by the Moonlight Serenade Orchestra and a ...
(Date:8/4/2015)... ... 2015 , ... Centurion Service Group, the world's largest medical equipment auction house, ... , The live auction will take place on Thursday, August 6 beginning ... at 5025 North Hiatus Road Sunrise, FL 33351. Anyone can participate in the auction ...
(Date:8/4/2015)... ... August 04, 2015 , ... Dr. Gary Richter, ... America’s Favorite Veterinarian. The contest is put on by the American Veterinary Medical ... nominees. Nominees were evaluated on community involvement, ethical behavior, passion for profession, and ...
(Date:8/4/2015)... ... August 04, 2015 , ... The goal of looking ... the desire for invasive surgery to achieve this ideal is not. But minimally invasive ... crave without the high cost or lengthy recovery time, according to Valerie Goldburt, ...
(Date:8/4/2015)... ... August 04, 2015 , ... The Law Offices of Ben C. ... claims dealing with Inferior Vena Cava Filters (“IVC Filters”). , As lead IVC filter ... Cook IVC Filter clients under In re Cook Medical, Inc., IVC Filters Marketing, Sales ...
Breaking Medicine News(10 mins):Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Medical Equipment Auction to Take Place in Fort Lauderdale 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 3
... , , , , ... The Ohio Nurses Association/Youngstown General Duty Nurses Association (ONA/YGDNA) ratified a ... process has resulted in the Registered Nurses of Northside Medical Center ... It is now up to the Forum Health management and ...
... , ANNAPOLIS, Md., July 27 ... company developing medical countermeasures against biological and chemical threats, today ... of 2-year, 10% unsecured senior convertible notes ("Notes") and common ... $19.3 million. , , In connection with ...
... BOZEN, Italy, July 27 Health Robotics today ... i.v.SOFT in order to market,implement, and support its I.V. ... infusion centers in North America. One of,its software modules ... at the University of Colorado Hospital [Denver], ...
... , , FRANKLIN LAKES, N.J., ... living in the country,s fifth largest city are now faced with ... Many commonly used therapy classes including drugs to treat diabetes, high ... in adults 20 and older. , , ...
... , , , Trinitas ... has new oral chemotherapy program in place ... availability of oral chemotherapy for treating a variety of cancers--along with projections ... drugs will be in oral form by 2013--raise questions for both clinicians ...
... , COLD SPRING HARBOR, N.Y., July 27 ... hand-held, non-contact vein illumination device, today announced that its quality ... Certification. This certifies to customers around the globe AccuVein,s commitment ... development, production, installation and delivery procedures. , ...
Cached Medicine News:Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 2Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 3Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 4Health News:Health Robotics Announces American Joint Venture With i.v.SOFT 2Health News:Health Robotics Announces American Joint Venture With i.v.SOFT 3Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 2Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 3Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 4Health News:Oral Chemotherapy Offers Patients a More Convenient, Less Invasive Treatment Option 2Health News:Oral Chemotherapy Offers Patients a More Convenient, Less Invasive Treatment Option 3Health News:AccuVein Achieves Quality System Milestone 2
Near PT test card/Tumbling E, tumbling hands 5 1/2" X 8"....
... PowerLab 2/25 is an economically priced ... teaching and research use in the ... pharmacology, neurophysiology, biology, zoology, biochemistry and ... all ADInstruments signal conditioners and transducers. ...
... Biomuse, a powerful, 8 channel "biocontroller" that ... bioelectric signal, and then outputs code to ... is intended for use as a development ... has licensed the Biomuse to selected research ...
They employ Lea Symbols. Contrast levels are the same at 25%, 10%, 5%, 2.5% and 1.25%. Each offers a different set of Lea Symbols to guard against memorization. Also uses recording forms (P/N 215400)...
Medicine Products: